How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists

The most common forms of B-cell malignancy, non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), have seen a drastic shift in the treatment landscape over the last two decades with the introduction of targeted agents. Among them are Bruton’s tyrosine kinase (BTK) inhibitors, which have...

Descripción completa

Detalles Bibliográficos
Autores principales: Nixon, Shannon, Duquette, Dominic, Doucette, Sarah, Larouche, Jean-Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137400/
https://www.ncbi.nlm.nih.gov/pubmed/37185435
http://dx.doi.org/10.3390/curroncol30040322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137400/
https://www.ncbi.nlm.nih.gov/pubmed/37185435
http://dx.doi.org/10.3390/curroncol30040322

Ejemplares similares